Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website
HSRD Conference Logo



2019 HSR&D/QUERI National Conference Abstract

Printable View

4010 — Comparative Safety Of Medications For The Treatment Of Insomnia And Suicidal Behavior In The US Department Of Veterans Affairs

Lead/Presenter: Jill Lavigne,  Center of Excellence for Suicide Prevention
All Authors: Lavigne JE (Center of Excellence for Suicide Prevention), Hur K (VA MedSAFE, Pharmacy Benefit Management), Kane C (Center of Excellence for Suicide Prevention) Au A (VA MedSAFE, Pharmacy Benefit Management) Bishop TM (Center of Excellence for Suicide Prevention) Pigeon WR (Center of Excellence for Suicide Prevention)

Objectives:
To assess the comparative effectiveness of the safety of medications routinely used to treat insomnia in VA.

Methods:
DESIGN: Comparative effectiveness using propensity score-matched samples. SETTING: VA. PARTICIPANTS: VA patients without any history of suicidal ideation or behavior 12 months prior to first exposure. EXPOSURES: VA formularies and data were used to identify prescriptions for insomnia. Agents accounting for at least 1% of total insomnia fill volume were < 200 mg trazodone, hydproxyzine, diphenhydramine, zolpidem, lorazepam, diazepam and temazepam. Exposure was defined as an incident monotherapy exposure preceded by 12-months without any insomnia medications. Subjects with insomnia polypharmacy or cross-overs in the 12 months following first exposure were excluded. MAIN OUTCOMES AND MEASURES: Suicide attempts within 12 months of first exposure.

Results:
348,449 subjects met criteria and three well-balanced cohorts by drug class matched to zolpidem were created. After adjusting for days' supply, mental health history and, pain and central nervous system medication history, hazard ratios (compared to zolpidem) were as follows: ( < 200mg) trazodone (HR = 1.61, 95% CI: 1.07-2.43); sedating antihistamines (HR = 1.37, 95% CI: 0.90-2.07) and benzodiazepines (HR = 1.31, 95% CI: 0.85-2.08).

Implications:
Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone ( < 200mg) . No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia.

Impacts:
Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence. The Department of Veterans Health Affairs (VA) fills high volumes of inexpensive, over-the-counter sedating antihistamines and older antidepressants in addition to benzodiazepines and zolpidem. Yet little is known about the comparative safety of these agents with regard to suicidal behavior.